Insider Selling: Regenxbio Inc (RGNX) SVP Sells $329,800.00 in Stock
Regenxbio Inc (NASDAQ:RGNX) SVP Patrick J. Christmas sold 5,000 shares of the firm’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $65.96, for a total transaction of $329,800.00. Following the sale, the senior vice president now directly owns 22,669 shares of the company’s stock, valued at $1,495,247.24. The transaction was disclosed in a document filed with the SEC, which is available at this link.
NASDAQ RGNX opened at $66.15 on Friday. Regenxbio Inc has a 12 month low of $19.45 and a 12 month high of $85.10. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of 34.14, a P/E/G ratio of 8.41 and a beta of -1.16.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported $0.30 EPS for the quarter, missing the Zacks’ consensus estimate of $1.23 by ($0.93). Regenxbio had a net margin of 44.44% and a return on equity of 28.70%. The company had revenue of $40.03 million for the quarter, compared to the consensus estimate of $100.00 million. equities research analysts predict that Regenxbio Inc will post 2.63 earnings per share for the current fiscal year.
RGNX has been the subject of a number of recent analyst reports. Bank of America lowered shares of Regenxbio from a “buy” rating to a “neutral” rating and raised their price target for the company from $64.00 to $80.00 in a report on Monday, July 23rd. Chardan Capital raised their price target on shares of Regenxbio from $90.00 to $130.00 and gave the company a “buy” rating in a report on Monday, July 16th. BidaskClub raised shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a report on Friday, June 1st. Morgan Stanley raised their price target on shares of Regenxbio from $37.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, July 13th. Finally, TheStreet raised shares of Regenxbio from a “d+” rating to a “c” rating in a report on Friday, May 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $74.79.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
See Also: Should I invest in “strong buy” stocks?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.